TARGET LEVELS OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM COMPONENTS AND THEIR ROLE IN CARDIOVASCULAR EVENT DEVELOPMENT AMONG PATIENTS WITH ARTERIAL HYPERTENSION
Abstract
The aim of this study was to identify the optimal, characterised by minimal risk of cardiovascular events (CVE), levels of renin-angiotensin-aldosterone system (RAAS) components in patients with arterial hypertension (AH). In total, 454 patients with high-risk AH were examined (age 18-65 years; 92 men, 362 women). Plasma renin activity (PRA) and plasma aldosterone concentration (PAC) were assessed by radio-immune method, adrenalin and noradrenalin concentration in 24-hour urine sample – by fluorometric method, left ventricular myocardial structure and function – by echocardiography, renal function – by glomerular filtration rate (Reberg method) and 123 I-Hippuran renography. Target levels of RAAS components were defined as follows: PRA=0,22-3,0 ng/ml/h, if PAC: PRA=5-23 and PAC=0,18- 0,83 nmol/l (5-23 ng/dl). In patients with high CVE risk, the target levels of PRA=0,22-1,0 ng/ml/h and PAC: PRA=5-23 would minimize the risk of stroke, myocardial infarction, and target organ damage.
About the Authors
Sh. V. Akhadov
Городская поликлиника №81 САО
Russian Federation
Russian Federation
G. R. Ruzbanova
Городская поликлиника №81 САО
Russian Federation
Russian Federation
G. S. Molchanova
Московский областной научно-исследовательский клинический институт им. М.Ф.Владимирского, Москва
Russian Federation
Russian Federation
T. G. Talalaeva
Московский областной научно-исследовательский клинический институт им. М.Ф.Владимирского, Москва
Russian Federation
Russian Federation
S. N. Khoreva
Московский областной научно-исследовательский клинический институт им. М.Ф.Владимирского, Москва
Russian Federation
Russian Federation
References
1. Шальнова С.А, Баланова Ю.А, Константинов В.В. и др. Артериальная гипертензия: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации// Росcийский кардиологический ж. 2006; 60; 45-50.
2. Agabiti-Rosei E, Muiesan M.I. Hypertensive left ventricular hypertrophy: pathophysiological and clinical issues// Blood Press 2001; 10; 288-98.
3. Brasier AR, Recinos A,3rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system// Arteroscler Thromb Vasc Biol 2002; 22:1257-66.
4. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in men. Anatomic validation of the method// Circulation.1977;55(4):613-618.
5. Diez J. Profibrotic effects of angiotensin|| in heart: a matter of mediaters//Hypertension 2004; 43;1164-5.
6. Ganou A, Devereux R, Raman M. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension// J Am. Coll. Cardiology 1992;19;1550-1558.
7. Karalliedde J, Viberti G. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes// J Hum Hypertens 2006; 20:239-53.
8. Schlaich MP, Schobel HP, Hilgers K, Schmieder RE. Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subiects// Am.J Cardiol 2000, 85, 1199-206.
9. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiolody// 2007 Guidelines for the management of arterial hypertension// J Hypertens 2007; 25: 1105–1187).
10. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five Euopean countries, Canada, and the United States//Hypertension 2004; 43; 10-7.
Review
For citations:
Akhadov Sh.V., Ruzbanova G.R., Molchanova G.S., Talalaeva T.G., Khoreva S.N. TARGET LEVELS OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM COMPONENTS AND THEIR ROLE IN CARDIOVASCULAR EVENT DEVELOPMENT AMONG PATIENTS WITH ARTERIAL HYPERTENSION. Russian Journal of Cardiology. 2009;(3):26-32. (In Russ.)
Views:
524
Email this article 